Abstract: A method for manufacturing a fiber-containing sheet. In extruding resin into sheet form using a T-die, the extrusion from the T-die is performed with a first resin for forming a core layer and a second resin for forming both skin layers on both sides of the core layer laminated together. The first resin contains fiber material and the second resin does not contain fiber material.

Abstract: An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon ?, interferon ?, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.

Abstract: An enhancer of expression, in the myeloma cell, of HM1.24 antigen, said enhancer comprising interferon-? or interferon-?, or IRF-2 protein as an active ingredient. Interferon-? or interferon-? is expected to enhance the expression of HM1.24 antigen by activating the promoter of a gene encoding HM1.24 antigen.

Abstract: To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. The results suggested that the 2D7 antigen is an HLA class I molecule. Based on this finding, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.

Abstract: An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon ?, interferon ?, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.

Abstract: An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon ?, interferon ?, or the IRF-2 protein as an active ingredient, as well as an anti-tumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.

Abstract: There is provided a process for producing a precursor film for a polypropylene-based resin retardation film that can yield films with almost no orientation and with high transparency. The process for producing a precursor film for a polypropylene-based resin retardation film comprises a step of pressing a molten sheet formed by extruding a molten polypropylene-based resin from a T-shaped die 12 at 180° C. or higher and 300° C. or lower between a cooling roll 16 having a surface temperature regulated to ?5° C. or higher and 30° C. or lower and a touch roll 14 having a surface temperature regulated to 80° C. or higher and 150° C. or lower, whereby the molten sheet is cooled and solidified.

Abstract: The present invention describes therapeutic agents for chemotherapeutic agent-resistant cancers that include an HLA class I-recognizing antibody as an active ingredient. A further objective of the present invention is to provide methods for treating chemotherapeutic agent-resistant cancers that include the step of administering an HLA class I-recognizing antibody to a subject. It is herein demonstrated that cytotoxic activity due to C3B3 diabody is induced at a lower concentration in chemotherapeutic agent-resistant hematological tumor cell lines having high MDR1 and HLA class IA protein expression, than in their parent cell lines. It was also found that when the chemotherapeutic agent-resistant hematological tumor cell line is pretreated with a C3B3 diabody, cell injury associated with sole use of chemotherapeutic agent is enhanced and the amount of pharmaceutical agents taken up into cells are increased.

Abstract: The present inventors tested the effects of interferons on the expression of HLA-A in cells and cell injury caused by anti-HLA class I antibodies, by using a 2D7-DB antibody as an anti-HLA class I antibody and the IM-9 cell line as the cells to be tested. As a result, the expression of HLA-A was demonstrated to be upregulated by IFN? or IFN?, Furthermore, WST-8 assays were performed to examine the cell viability when an interferon and an anti-HLA class I antibody were used in combination. As a result, cell death activity was found to be increased by the combination of 2D7-DB and IFN? or IFN?.

Abstract: To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. As a result, the 2D7 antibody was found to recognize HLA class IA. In addition, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.

Abstract: To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. The results suggested that the 2D7 antigen is an HLA class I molecule. Based on this finding, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.

Abstract: An enhancer of expression, in the myeloma cell, of HM1.24 antigen, said enhancer comprising interferon-? or interferon-?, or IRF-2 protein as an active ingredient. Interferon-? or interferon-? is expected to enhance the expression of HM1.24 antigen by activating the promoter of a gene encoding HM1.24 antigen.

Abstract: An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon ?, interferon ?, or the IRF-2 protein as an active ingredient, as well as an anti-tumor agent for hematopoietic tumors which comprises a combination of said inducing agent or enhancing agent and an antibody against HM1.24.